CTMX CytomX Therapeutics Inc: Earnings per one share for the last 12 months

This price visualization for CytomX Therapeutics (CTMX), which assists in the basic asset valuation, demonstrates an EPS of -211.20. The business's financial stability relies on partner payments and adherence to clinical trial schedules. CytomX Therapeutics (CTMX) creates unique targeted delivery systems for neoplasms, making it an attractive counterparty for pharmaceutical behemoths. In the long term, profits will be generated through the commercialization of innovative Probody drugs.
CytomX Therapeutics Inc - analytical breakdowns and key metrics (CTMX)

This indicator reflects the sensitivity of net earnings per share to changes in cash flows by comparing rolling annual periods. The metric measures the growth rate of earnings over the last twelve months, excluding one-time accounting distortions. For CytomX Therapeutics (CTMX), this trend demonstrates the effectiveness of investments in the pro-antibody platform for targeted tumor therapy. By analyzing the year-over-year EPS history (over 12 months), an investor can detect a trend reversal in a timely manner.